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ABSTRACT
Introduction: Drug resistance among bacteria is a scourge to patients and infectious disease and
infection control specialists. The rapid detection of resistance is a challenge for clinical microbiologists
who wish to prevent deleterious individual and collective consequences such as (i) delaying efficient
antibiotic therapy, which worsens the survival rate of the most severely ill patients, or (ii) delaying the
isolation of the carriers of multidrug-resistant bacteria and promoting outbreaks; this last consequence
is of special concern, and there are an increasing number of approaches and market-based solutions in
response.
Areas covered: β-lactams are the cornerstone of numerous empirical and definitive antimicrobial
strategies. From simple, cheap biochemical tests to whole-genome sequencing, clinical microbiologists
must select the most adequate phenotypic and genotypic tools to promptly detect and confirm β-
lactam resistance from cultivated bacteria or from clinical specimens. Here, the authors review the
published literature from the last 5 years about the primary technical approaches and commercial
laboratory reagents for these purposes, including molecular, biochemical and immune assays.
Furthermore, the authors discuss their intrinsic and relative performance, and we challenge their
putative clinical impact.
Expert commentary: Until the availability of fully automated wet and dry whole genome sequencing
solutions, microbiologists should focus on inexpensive biochemical tests for cultured isolates or mono-
microbial clinical specimen and on using the expensive molecular PCR-based strategies for the targeted
screening of complex biological environments (such as stool or respiratory tract clinical specimens).
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1. Introduction
1.1. General statements
Several factors are key elements with respect to the emer-
gence of new bacterial agents, such as the acquisition of
virulence factors, an increasing capacity for rapid spreading,
and the development of antimicrobial resistance [1]. This last
property has broken the ‘antibiotic dream’ that occurred after
the discovery of penicillin, and it defies the 20th century belief
that natural, semi-synthetic, and synthetic drugs might defini-
tively treat any type of bacterial infection [2]. In the USA, the
number of patients who are infected with antibiotic-resistant
bacteria has reached 2 million people each year, 23,000 of
whom had fatal outcomes [3]. ß-Lactams remain the corner-
stone of antibacterial treatments [4]. We are now facing a
continuous race between the marketing of new ß-lactam
compounds and the in vivo selection of ß-lactamases with
increased or wider hydrolytic activities, particularly in gram-
negative bacteria [1,4]. Enterobacteriaceae and, more specifi-
cally, Escherichia coli, include the most important sources of
severe bacterial infections in humans for illnesses such as
bloodstream infections [5]. From a human perspective, our
ability to detect these resistant bacteria at the bedside of
infected patients and to optimize antibiotic stewardship are
among the essential steps in controlling the vicious circle of
antimicrobial resistance. Here, we focus on advances in the
rapid detection of ß-lactam resistance amongst the
Enterobacteriaceae.
1.2. What is rapid detection testing?
A rapid detection test should provide results within a two-
hour turnaround time (TAT) according to the workflow
observed in many clinical laboratories [6]. We can distinguish
between the standard analytical time and the current TAT.
Beyond the bench procedure in the laboratory, the TAT
includes the time between the prescription of the test and
the availability of the results to clinicians. Point-of-care tests
(POCTs) that deliver results within 30 min of specimen collec-
tion could be performed at the patient’s bedside by a
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which should be cited to refer to this work.
physician or nurse. As a reminder, the culture-based techni-
ques used as a reference here have a TAT of 18 h or longer.
Moreover, the complete process of a culture-based approach
requires selective screening media, antimicrobial susceptibility
testing, and confirmatory tests; each of these steps lasts
16–20 h, which corresponds to the need to obtain a bacterial
culture. Consequently, all the methods that appear in the
literature as ‘detection tests’ but require overnight growth to
produce results are outside the scope of this work. This is the
case, for example, for the Carbapenemase Detection Set®
used to detect carbapenemase-producing bacteria (MAST-
CDS, Mast Group, Merseyside, U.K.) [7]. Beyond carbapene-
mase detection, the use of specific inhibitors allows for the
identification of the different enzyme subgroups on the same
day or on the following day at a low additional cost [8]. As
further reported, the ongoing development of automated
digital analysis could accelerate the detection of bacterial
growth and may decrease the TAT of these methods [9].
1.3. Relevance of the subject
1.3.1. Contribution of rapid detection tests to
antimicrobial stewardship
Next to infection control measures, antimicrobial stewardship
is the cornerstone of the fight against multidrug-resistant
microorganisms (MDRO). The implementation of an antimicro-
bial stewardship program is based on a series of measures
such as the elaboration of empirical antibiotic therapy proce-
dures, skilled expertise among infectious disease consultants,
control-of-last-resort antimicrobial compounds, and the avail-
ability of laboratory-based tools to confirm the bacterial origin
of sepsis (e.g. the procalcitonin dosage) and to detect resis-
tance-related traits as soon as possible [10]. This last segment
of the laboratory’s contribution to antimicrobial stewardship
allows for a narrower empirical antimicrobial spectrum and
the de-escalation (i.e. the reduction of the antimicrobial spec-
trum) of the ultimate targeted therapy. Furthermore, the rapid
detection of a resistant trait may allow us to upgrade the
antibiotic strategy in case of inadequate empirical therapy.
At present, this detection is a hot topic and a top priority for
clinical microbiologists [6]. Rapid detection tests clearly belong
to this armamentarium.
1.3.2. The key role of β-lactam antibiotics in antimicrobial
chemotherapy
According to their intrinsic properties, such as bactericidal
activity, low toxicity and few side effects, a wide spectrum of
activity, excellent pharmacokinetic parameters, and relatively
low price, β-lactams are among the most frequently pre-
scribed antimicrobial agents, ranking first in human medicine
and second in veterinary medicine [11,12]. The fact that they
are prescribed for treating community-acquired infections as
well as severe nosocomial infections is due to their wide
spectrum of antibacterial activity.
1.3.3. The evolving world of ß-lactamases in
Enterobacteriaceae: an endless race?
The diversity of β-lactamases identified in Enterobacteriaceae is
high in contrast to the diversity of clinically relevant,
multidrug-resistant gram-positive bacteria such as vancomy-
cin-resistant Enterococci (VRE) or methicillin-resistant
Staphylococcus aureus (MRSA) in which the variety of resistant
genes responsible for key antimicrobial compounds (i.e. ß-
lactams or glycopeptides) is limited, including one or two
genes (mecA/C, vanA/B) [4]. Regarding Staphylococci, it is nota-
ble that a significant percentage of the clinical strains (40–
80%) produce penicillinase, of which different types have been
described. The Ambler scheme classifies β-lactamases into four
classes (A, B, C, and D) according to the protein homology of
enzymes. Considering the current challenges in antimicrobial
therapy and infection control, there will be a focus on the two
families of ß-lactamases found in Enterobacteriaceae, the class
A extended-spectrum β-lactamases (ESBL) and the carbapene-
mases that gather enzymes from the class A, B, and D groups
[4]. Plasmid-encoded AmpC-type β-lactamases belong to
Ambler class C and are less relevant than ESBL and carbape-
nemase in terms of public health. Nevertheless, this class
should be monitored with caution. ESBLs inactivate the pri-
mary first-line therapy for gram-negative bacteria, namely the
expanded cephalosporins (cefotaxime, ceftriaxone, ceftazi-
dime, and cefepime). The most commonly identified ESBLs in
Enterobacteriaceae to date are the CTX-M enzymes, followed
by the TEM and SHV derivatives. Carbapenemases inactivate
carbapenems, and they may either possess a serine residue in
their active site (class A and class D β-lactamases) or require
zinc ions in their active sites to be functional (class B ß-
lactamases, which are also named metallo-β-lactamases). The
most commonly identified carbapenemases in
Enterobacteriaceae are the class A ß-lactamase KPC, the class
B IMP-, VIM-, and NDM- enzymes, and the class D OXA-48-like
enzymes. The biochemical diversity of carbapenemases leads
to a degree of variability in the hydrolysis profiles; it constitu-
tes an additional challenge for their detection. The hydrolysis
and inactivation of carbapenems, which are the primary last-
resort antimicrobial compounds, constitute a real threat to
public health [13].
1.3.4. Impact of ß-lactam resistance detection on clinical
success: the individual point of view
Resistance to β-lactams is a risk factor for therapeutic failure,
and, for some special situations, it is a risk factor for death.
With regard to empirical therapy, the delayed administration
of an effective therapy has a negative effect on the clinical
outcome such as the clinical cure, length of hospitalization, or,
for the most severe infections or the weakest patients, the
survival rate [14]. This relationship is clearly established parti-
cularly for septic shock. Considering the definitive therapeutic
option, resistance to β-lactams is associated with poor out-
come, with infections caused by ESBL- or carbapenemase-
producing strains associated with a higher mortality rate. For
example, the mortality caused by Klebsiella pneumoniae bac-
teraemia is significantly increased if the given strains are
resistant to carbapenems [15,16].
1.3.5. Impact of MDRO detection on infection control
policy success: the collective point of view
The efficacy of the ‘search and destroy’ policy is strongly
associated with the rapid implementation of the appropriate
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infection control measures such as patient isolation and dedi-
cated health-care staff [17]. In 2014, Fournier and colleagues
showed that the implementation of extensive infection control
measures during the first 48 h of the hospitalization of an
MDRO carrier is statistically associated with fewer secondary
cases compared to the results of delayed strategies [18]. The
multiplicity of patients requiring isolation measures is asso-
ciated with decreased hygiene compliance [19].
1.4. Practical aspects of the topic
The rapid detection of antibiotic resistance can be considered
at the different steps of the microbiological diagnosis process,
either directly from clinical specimens or after a primary cul-
ture step (from broth cultures such as blood cultures or agar-
based cultures), from carriers or infected patients. The putative
contribution of these tests is summarized in Table 1.
Some issues that are discussed later could be extended to
the management of other MDROs, including gram-positive
bacteria (VRE and MRSA) and non-fermentative Pseudomonas
aeruginosa and Acinetobacter baumannii. Nevertheless, the
impact of the rapid detection of those two bacteria at the
species level and in terms of resistance traits is primarily
limited to intensive care units. Beyond the focus on a single
antibiotic class, i.e. the ß-lactams, we targeted a particular
resistance mechanism, which is the production of β-lacta-
mases, the enzymes that inactivate the β-lactam ring that is
responsible for antimicrobial activity. Along with the produc-
tion of β-lactamases, additional mechanisms have been
described to be responsible for β-lactam resistance such as
efflux pumps, penicillin-binding protein modifications, and the
decreased production or loss of porins. However, the most
significant mechanism of ß-lactam resistance either clinically
or epidemiologically in Enterobacteriaceae remains the pro-
duction of ß-lactamases. Since the genes that encode β-lacta-
mases might be transferable, facilitating their detection to
improve their control is of paramount importance for control-
ling their spread. Among the very large panel of β-lactam
compounds that includes penicillin, cephalosporins, monobac-
tams, and carbapenems, we focused on two categories of
antibiotics, the broad-spectrum third-generation cephalospor-
ins (3GC) and the carbapenems. Due to their low cost, great
clinical efficiency, and global availability inside and outside of
hospitals, the 3GC constitutes a first-line choice for empirical
and definitive therapy in many cases. However, carbapenems
constitute last-resort options for which the clinical efficiency
and tolerability are higher than that of alternative anti-
biotherapies such as polymyxins or tigecycline.
2. Biochemical diagnostics for rapid detection of
antibiotic-resistant enterobacteriaceae
2.1. What is the gold standard for the biochemical
detection of β-lactam-resistant Enterobacteriaceae?
The definition of the gold standard in antimicrobial testing for
clinical purposes is one of the most important issues for
microbiologists and clinicians. From a biochemical point of
view, the gold standard for the biochemical characterization
of a β-lactamase requires the lysis of the cell, the purification
of the proteins, the analytic isoelectric focusing of the extract,
and the identification of its hydrolytic activity using a penicillin
such as Nitrocefin® (Oxoid, Hampshire, U.K.). Beyond this basic
characterization, the hydrolytic activity spectrum should be
measured using an UV spectrophotometer against a panel of
β-lactam compounds and inhibitors; the specific activity and
kinetics parameters could then be established. Clearly, this
method may take days and may not be implemented as part
of a clinical approach that requires prompt results to optimize
the therapeutic options.
2.2. Recent advances in biochemical diagnostics for
the rapid detection of antibiotic-resistant
Enterobacteriaceae
The identification of broad-spectrum ß-lactamase activity is
the cornerstone of the biochemical approach to rapidly
detecting broad-spectrum β-lactam resistance. Due to the
high diversity and prevalence of β-lactamases among
Enterobacteriaceae, the biochemical approach should be
more selective, focusing on ESBL and carbapenemase produc-
Table 1. Key challenges in antimicrobial chemotherapy and putative contribution of the rapid diagnostic techniques in clinical laboratory.
Key challenge
ResponsesAt the individual level At the community level
-To identify the carriers of
bacteria resistant to antibiotics
-To rapidly identify the carriers of MDROa and to
prevent cross transmission by implementing
isolation measures
-To identify risk factors for resistant bacteria carriage as history of
antibiotic consumption or hospitalization
-To identify history of MDRO carriage
-To detect MDRO carriage using selective culture-based approach and to
confirm the presence of resistance traits
-To detect resistance traits directly from clinical specimens
-To identify resistant traits
among bacteria responsible
for sepsis
-To limit the use of empiric broad range
antimicrobial therapy
-To perform culture-based diagnosis of bacteria responsible for sepsis
and to perform antimicrobial susceptibility testing/to detect resistant
traits from cultivated bacteria
-To avoid extensive impact onto
the natural microbiota,
especially the intestinal
microbiota, that promote the
acquisition of Clostridium
difficile or drug-resistant
bacteria
-To detect resistance traits directly from biological specimen
aMultidrug-resistant organisms.
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tion. Two approaches have been developed for this detection,
the colorimetric approach and the use of matrix-assisted laser
desorption ionization-time of flight mass spectrometry
(MALDI-TOF) technology.
2.2.1. The colorimetric approach
The colorimetric approach consists in obtaining a variation in
the color of the reagent medium resulting from a hydrolytic
activity that modifies the chemical composition of the med-
ium. This variation could be detected by eye or it could be
measured by a spectrophotometer.
2.2.1.1. The use of a chromogenic substrate to detect the
ß-lactam hydrolysis capacity of bacteria. The principle of
this approach is to specifically select a substrate for the tar-
geted enzymes; the hydrolysis of this enzyme would lead to
the production of a product that shows a different color
relative to the initial color of the substrate. The ancestral
example of this approach was the Cefinase® test that was
marketed in the early 1970s to detect the penicillinase of S.
aureus. Nitrocefin (Oxoid, Hampshire, U.K.) was reported in
1972 as a chromogenic cephalosporin that acted as a sub-
strate for any type of β-lactamases [20]. This substrate cannot
differentiate between narrow- and extended-spectrum β-lac-
tamases (ESBLs) in Enterobacteriaceae. Some authors have
attempted to improve this test by adding β-lactamase-specific
inhibitors and optical density measurements (i.e. the Penta-
well test), but neither ESBLs nor carbapenemases could be
accurately identified [21].
2.2.1.1.1. The detection of ESBL activity. The β-Lacta test®
(Bio-Rad, Marnes-La-Coquette, France) is the first commercial
kit for using this approach to detect ESBL-producing
Enterobacteriaceae [22]. It consists of a chromogenic substrate
(HMRZ-86) that was discovered more than 10 years ago. This
substrate resists narrow-spectrum β-lactamases but is hydro-
lyzed in the presence of an ESBL, yielding a red product; an
orange color should be considered an equivocal, undeter-
mined result (Figure 1) [23]. The β-Lacta test® was first used
with isolated colonies and was then conducted directly from
clinical specimens such as urine or blood cultures [24–26]. The
characteristics and performance of this test are reported in
Table 2. The β-Lacta test® was initially developed to detect all
the broad-spectrum ß-lactamases that hydrolyze cephalospor-
ins. This test not only detects ESBLs but also some hyperpro-
duced cephalosporinases and some carbapenemases with
activity toward expanded-spectrum cephalosporins [27]. The
β-Lacta test® may be performed in parallel with a rapid iden-
tification method, such as MALDI-TOF MS [24,25]. Although
the sensitivity of this test for detecting ESBL-producing
Enterobacteriaceae is high, the positive predictive value is
rather low because this test also detects AmpC hyperprodu-
cers, the class A carbapenemase KPC, the OXA-48-like class D
carbapenemases, and, at a lower efficacy, the class B carbape-
nemase producers [27].
2.2.1.1.2. Detection of carbapenemase activity. The β-CARBA
test® (Bio-Rad, Marnes-La-Coquette, France) has recently been
marketed for the detection of carbapenemase among freshly
isolated Enterobacteriaceae colonies; it employs a chromogenic
substrate (http://www.bio-rad.com/fr-fr/sku/68260-beta-carba-
test). The color change in the reactive medium must be visua-
lized by eye within 30 min. The bacterial culture must be fresh
(<24 h). The manufacturer of the β-CARBA test® reports a
sensitivity of 100% (207/207) when testing colonies that
were obtained on Columbia agar containing 5% sheep
blood, and they also report a specificity of 97.8% (89/81).
The sensitivity decreases significantly if the colonies are picked
from a chromogenic (98.6%) or Drigalski (77.6%) medium. The
false-positive non-carbapenemase-producing strains were
AmpC producers. Recently, Compain et al. tested the β-
CARBA test® against a collection of 42 carbapenem-resistant
Enterobacteriaceae, with 30 out of 42 being carbapenemase
producers [29]. Within the 30 min of incubation recommended
by the manufacturer, the test was positive for 26 of the
carbapenemase-producing strains, missing four OXA-48-pro-
ducing E. coli; these missed strains yielded a positive test result
if the incubation was prolonged to 1 h. No false-positive
results were obtained. Since only a single published study is
available, those data will be treated with caution, and they
require further clinical validation.
2.2.1.2. The use of a non-chromogenic substrate in which
hydrolysis leads to a color change in the medium
2.2.1.2.1. Detection of ESBLs. The newly marketed Rapid
ESBL NP Test® (Senova GmbH, Weimar, Germany) is an
Carbapenemase
chromogenic
substrate
2 - 15  minutes
coloured
product
_
? +
Figure 1. The β -lacta Test®.
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upgraded version of the ESBL NDP test that was first devel-
oped as a home-made test for detecting the hydrolysis of
cefotaxime (and any other broad-spectrum cephalosporins)
in less than 20 min by using a pH indicator (phenol red) [30].
In comparison to a negative control well without antibiotic,
the reactive well containing cefotaxime and the pH indicator
experiences a color change from red to yellow if ESBL pro-
duces some carboxyl-acid groups resulting from cefotaxime
hydrolysis. The same reaction occurs in the presence of a
penicillinase inhibitor, namely tazobactam, which inhibits the
hydrolysis reaction, thereby helping to identify the ESBL nat-
ure of the ß-lactamase (Figure 2). The performance of this
home-made test has been evaluated with either cultured
bacteria (sensitivity, 92.6%; specificity, 100%) or directly from
urine (sensitivity, 98%; specificity, 99.8%) or positive blood
culture samples (sensitivity, 100%; specificity, 100%). Its sensi-
tivity is excellent, particularly for detecting CTX-M producers
(100%) [30–32]. A copy of the ESBL NDP test has been mar-
keted (the Rapid ESBL Screen kit®, Rosco-Diagnostica,
Tasstrup, Denmark); neither the specific characteristics nor
performance results are published. A performance comparison
of three tests for detecting the ESBL-producing bacteria (the
rapid ESBL NDP test, the Rapid ESBL Screen kit®, and the β-
Lacta test®) was recently performed using the exact same
collection of strains [28]. The ESBL NDP test reached high
sensitivity and specificity (95% and 100%, respectively). The
limits of the β-Lacta test® in selectively detecting the ESBL-
producing bacteria among cephalosporin-resistant
Enterobacteriaceae were again highlighted here (specificity,
71%). Regarding the Rapid ESBL Screen kit®, the protocol
appeared to be time-consuming (2 h) and the results varied
considerably according to the reading time. The sensitivity
and specificity of the Rapid ESBL Screen kit were lower than
those of the ESBL DP test.
2.2.1.2.2. Carbapenemase detection. The first commercial
test was the RAPIDEC® Carba NP test (bioMérieux, La Balme-
les-Grottes, France). The marketed version and its prototypes
(see later) are the most frequently evaluated methods for the
rapid detection of carbapenemase activity, with more than 60
published references, primarily in highly rated journals. This
test is an identical version of the original Carba NP test that
took advantage of several improvements. Notably, the Carba
NP test is now recommended as a first-line test for screening
carbapenemase activity by the Clinical and Laboratory
Standards Institute in the US [35]. This test targets any type
of carbapenemase activity by detecting the hydrolysis of imi-
penem. Originally, the Carba NP test was developed as an in-
house technique using imipenem as substrate, with the prin-
ciple of the test based on the acidification of the reaction
medium when the β-lactam ring of the imipenem molecule
is opened because of the hydrolytic activity of carbapene-
mases [36]. The modification of the pH of the reacting med-
ium is revealed by a color shift in the pH indicator, namely the
phenol red that turns from red to yellow with acidification
(Figure 3). Another version of the in-house Carba NP test, the
Carba NP II test, has been developed, and it includes
Table 2. Principle and performances of rapid biochemical tests for the detection of clinically relevant β-lactam-resistant Enterobacteriaceae.
Principle/name of the test
Targeted
enzymes
Required
additional
supplies
Delay for first/
definitive results
Performances on
cultured bacteria
Performances on clinical
specimen References
Colorimetric–chromogenic substrate
ß-Lacta test® ESBL
b None 15 min Sensitivity: 88%
Specificity: 71%
Urines: sensitivity: 94%,
specificity:100% (positive
blood culture: sensitivity:
95.7%, specificity: 100%)
[22–28]
β-CARBA test® Carbapenemase None 30 min No direct comparison:sensibility 87%,
specificity 100%
[29]
Colorimetric–non-chromogenic substrate
Rapid ESBL NP test® ESBL
b None 20 min Sensitivity: 95%
Specificity: 100%
Urines: sensitivity 98%,
specificity 99.8%, positive
blood culture: sensitivity
100%, specificity 100%
[28,30–32]
Rapid ESBL Screen kit® ESBL
b None 30 min/2 h Sensitivity: 92%
Specificity: 83%
[28]
Rapidec® Carba NP test Carbapenemase None 30 min/2 h Sensitivity: 99%Specificity: 100%
Positive blood culture:
preliminary experimental
data
[33]
Rapid CARB Screen® Carbapenemase None 5 min/2 h Sensitivity: 89.5%Specificity: 70.9%
[33]
Rapid Carb Blue kit® Carbapenemase None 15 min/1 h No direct comparison:sensitivity 100%,
specificity 100%
[34]
Mass spectrometry detection
Pending marketed kits from MALDI-
TOF MSa platforms manufacturers
Carbapenemase MALDI-TOF
MSa
platforms
1–4 h Sensitivity: 72.5%–
100%
Specificity:98%–100%
Positive blood culture:
preliminary experimental
data
aMatrix-assisted laser desorption ionization-time of flight mass spectrometry.
bExtended-spectrum ß-lactamase.
cNonevaluated.
Indications in brackets are not validated by the manufacturers.
Performances in bold are provide from direct comparisons (as the corresponding reference).
5
htt
p:/
/do
c.r
ero
.ch
additional wells with class-specific β-lactamase inhibitors
[37,38]. This version allows investigators to screen and to
more precisely characterize the carbapenemase activity of a
given strain, allowing them to differentiate between enzymes
for which the activity is inhibited by clavulanic acid (class A),
by EDTA (class B), or by neither of those two (class D). To date,
the Carba NP II test has not been developed industrially.
Interestingly, the hydrolytic activity of metallo-carbapene-
mases is boosted by reagent medium that includes zinc, a
basic element that is essential for metallo-β-lactamases. The
global use of the Carba NP test allowed for some improve-
ment of its performance, either for the recommended inocu-
lum particularly for mucoid strains, the nature of the
imipenem, or the type of agar medium from which tested
colonies are picked [39–43]. The sensitivity of the carbapene-
mase detection could be negatively influenced by several
culture media such as the Drigalski or MacConkey agar plates,
considering that colored pigments may interfere with the
N
O
R
COOH
S-R
Carbapenem
Imipenem
H2N
R
COOH
S-RO
HO
Production of acid
pH
Colorimetric 
detection
1 2 1 2
Carbapenemase 
production
No carbapenemase
Red Orange-Yellow
1 : Control solution without 
imipenem
2 : Solution with imipenem
Carbapenemase
Figure 3. The Carba NP ®Test.
Cephalosporin
cefotaxime
Hydrolysis
pH
Production of acid
Red Orange-Yellow
Extended-spectrum ß-lactamase (ESBL)
+
ß-lactamase 
inhibitor
tazobactam
No hydrolysis
Red Red
Figure 2. The ESBL NP ®Test.
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reading of the test [44]. This in-house method has been
improved several times and then industrially developed, and
it has been on the market since early 2015 under the trade
name RAPIDEC® Carba NP test (Figure 4) [45–50].
The ability of the RAPIDEC® Carba NP test to detect carba-
penemase activity depends at least in part on the level of
enzyme production and the enzyme’s capacity to hydrolyze
the substrate and the tested inoculum (see later). The perfor-
mance of the RAPIDEC® Carba NP makes this biochemical test
appropriate for the rapid (30 min to 2 h) and convenient
screening of carbapenemase activity in gram-negative bac-
teria. Its sensitivity and specificity reached 96% in the original
study, subsequently increasing to 97.8% and 98.5%, respec-
tively, during independent evaluations [45–47]. Some publica-
tions reported relatively low sensitivities for in-house and
RAPIDEC® Carba NP tests for detecting the OXA-48-type pro-
ducers [42,49,50]. Those results may be explained by the
weaker carbapenemase activity of the OXA-48-like carbapene-
mases, or the use of old cultures or too little inoculum.
Notably, the use of the correct inoculum (one full 10-μl loop
for the Carba NP test) and a proper culture plate are critical for
obtaining good sensitivity. The zinc concentration and/or the
color of the colonies on chromogenic medium must be opti-
mal for detecting the enzymatic activity with enough sensitiv-
ity [49]. Since the CarbaNP test® was successfully challenged
directly against positive blood cultures, ongoing studies are
evaluating the performance of the RAPIDEC® Carba NP
directly from clinical specimens (Pr Nordmann, personal com-
munication) [51].
Commercial alternatives to the RAPIDEC Carba NP test have
been developed to screen for carbapenemase activity, such as
the Neo-CARB kit®, which was formerly the Rapid CARB
Screen® or the Rapid Carb Blue kit® (Rosco Diagnostica A/S,
Taastrup, Denmark). The former is a copy of the RAPIDEC®
Carba NP and the latter test is identical to the RAPIDEC® Carba
NP, with the exception of the color indicator, which is bro-
mothymol blue instead of phenol red [34,39,52–54].
Furthermore, and beyond the performance of these tests in
the original publications, their direct comparisons against the
Carba NP test and/or the RAPIDEC® Carba NP showed super-
iority in terms of performance (Table 2) [33,55–57].
2.2.1.3. Advantages of the colorimetric approach. The col-
orimetric approach fulfills the requirements of an optimal test
for β-lactamase detection in that it is reliable, rapid, cheap,
and requires no or very limited additional supplies. The bio-
chemical detection of ESBL or carbapenemase activities per-
mits researchers to identify any type of enzyme, whereas
molecular-based techniques only detect the genes that are
included in the corresponding test.
One primary advantage of colorimetric approaches is that
they can be applied directly to colonies that are grown on
selective media for the rapid detection of multidrug-resistant
strains. For the detection of either ESBL- or carbapenemase-
producing bacteria, the ESBL NDP and the Carba NP tests are
perfectly suitable. The screening of MDRO carriers can there-
fore be optimized in terms of effectiveness, combining excel-
lent sensitivity and rapidity, which are two critical features in
infection control policy.
2.2.1.4. Pitfalls of the colorimetric approach. The expected
performance of colorimetric methods is based on their capa-
city to detect the hydrolysis activity of a broad range of
biochemically diverse enzymes (and therefore it has high sen-
sitivity) without amplifying nonspecific activities (therefore
providing highly specific results). The sensitivity of a biochem-
ical test with the aim of detecting an enzymatically mediated
mechanism of antibiotic resistance depends on different
factors such as (i) the amount of enzyme produced, which
relies on the level of expression of the corresponding gene
and the bacterial inoculum; (ii) the ability of the enzyme to
hydrolyze the substrate, which relies on the extraction proto-
col; (iii) the affinity of the enzyme for the substrate, which
relies on the pharmacokinetics properties of the enzyme/sub-
strate couple; and (iv) the sensitivity of the revelation step,
which relies on the indicator properties and the mode of
measurement (by naked eye or photometric means).
In addition to the lack of sensitivity, phenotypic colori-
metric tests might run into some interference from the unde-
sirable hydrolytic activities of nontargeted enzymes. This result
is found for intrinsic AmpC-type cephalosporinases from dif-
ferent enterobacterial species or the K1 penicillinase of
Klebsiella oxytoca, which hydrolyzes broad-spectrum cephalos-
porins when they are overproduced (ß-Lacta test®). Therefore,
determining an accurate threshold for phenotypic colorimetric
methods may be a critical issue. It is notable that the TAT of
some assays could exceed 2 h. Additionally, those tests are not
suitable for rectal screening due to the lack of specific recog-
nition of their ESBLs or carbapenemases among all the micro-
biome bacterial activity.
2.2.2. MALDI-TOF MS approach
2.2.2.1. Principle of the MALDI-TOF MS approach. The
implementation of MALDI-TOF MS technology in clinical
laboratories has significantly modified bacterial diagnostics.
Combined with the automation and implementation of a
user-friendly interface, the identification of bacteria by mass
spectrometry opens up a new area for microbiologists in terms
of accuracy and TAT to deliver results [58]. This technology
identifies the bacteria at the species and/or genus level from
single isolated colonies on solid media, but it is also applied
directly to positive blood and urine [58]. After a first rapid
preparation step including sample application to a slide and
the addition of an organic matrix solution, the identification
can be performed in less than 1 min. If a clinical fluid or a
positive blood culture is directly tested, a pre-processing step
has to be performed. The MALDI-TOF MS principle is based on
the ionization, with a laser source, of bacterial biomolecules
containing proteins embedded in a matrix. Once they are
ionized and sublimated into a gas phase, these molecules
are accelerated into an electric field and projected onto a
detector. They can then be separated and analyzed according
to their time of flight. This delay between the ionization
process and the final impact depends on their mass-to-charge
ratio.
Commercial MALDI-TOF technology focuses on the identi-
fication of proteins or DNA molecules [58]. Several systems are
on the market including different machines and databases; the
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three primary commercial products are the Bruker Biotyper®
(Bruker Daltonics, Wissenbourg, France), the bioMérieux Vitek
MS System® (bioMérieux, Marcy l’Etoile, France), and the
Andromas® (Beckman Coulter, Villepinte, France) system, the
database of which can be implemented in different machines.
Before bacterial identification using libraries of protein profiles
via the MALDI-TOF concept, MS technology was developed to
identify chemical compounds, including antibiotics. When
coupled with liquid or gas chromatography, MS is the refer-
ence method for detecting and dosing antibiotics in clinical
samples. Due to its cost and lack of user friendliness, this
approach was replaced by immunological techniques such as
ELISA. Nevertheless, MS maintains the capacity to detect anti-
microbial molecules and, interestingly in the context of β-
lactam resistance, the products of the antibiotic after hydro-
lysis. Therefore, MALDI-TOF MS has great potential for the
detection of resistance traits among bacteria strains in two
particular contexts, i.e. (i) the detection of the enzyme and (ii)
the detection of a substrate degradation replaced by the
signal of its product after a variable incubation time.
When dealing with β-lactamases, the identification of a
discriminatory peak corresponding to a protein with signifi-
cant hydrolysis activity was first considered, but it was rapidly
abandoned in favor of observing the degradation product
[58]. MALDI-TOF MS is used to identify both the β-lactam
molecule and its degradation product. As an example, the
hydrolysis of imipenem is interpreted as the disappearance/
appearance of specific peaks (300 Da and 254 Da, respectively)
when this antibiotic is added to a bacterial suspension, and
the MS spectrum is measured at the time of substrate addition
and after 20 min of incubation. The TAT of this process is
approximately 30 min [59]. Some other protocols are more
time-consuming, requiring an incubation time from 1 to 4 h
[60–62]. The performance of this approach depends on the
metabolite/imipenem ratio but also the metabolite cut-off. For
example, in Knox et al., the MALDI-TOF MS approach was
compared to the Carba NP test; the breakpoint was deter-
mined to be a disappearance of 95% of the area under the
curve for the test compared to the control replicate [60]. In
this study, the performance of the two methods was equiva-
lent. Beyond the various published home-made protocols with
differences in the substrate (meropenem/imipenem/ertape-
nem/faropenem), the lysis conditions, the incubation time,
and the parameters/breakpoints, a specific module should be
marketed in the very near future (MALDI Biotyper STAR BL®,
Bruker Daltonics, Wissenbourg, France) [63].
Additionally, the chemical properties of the enzyme may be
indirectly investigated by adding specific inhibitors (such as
the ß-lactamase inhibitor clavulanic acid) that hinder the β-
lactamase hydrolytic activity and therefore slow the disappear-
ance of the ß-lactam native peak. Several companies have
developed kits for that purpose, and they have produced
protocols that are about to be marketed. Some authors have
attempted to adapt the protocol to positive blood cultures,
and it is much more time-consuming (3–4 h) since a pre-
culture is needed to amplify the amount of bacteria in the
specimen [64,65]. Next to β-lactamase production, the loss of a
porin that allows the entry of the antibiotic inside the bacterial
cell constitutes a clinically and epidemiologically relevant
mechanism of resistance in Enterobacteriaceae. The MALDI-
TOF MS technology could replace cumbersome and time-con-
suming reference methods such as sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), which is labor-
ious to use routinely. For example, the loss of porins (OmpK35,
OmpK36) from Klebsiella species may lead to carbapenem
resistance The SDS-PAGE technique is the reference method
for identifying the presence/absence of these porins [66]. After
the identification of the corresponding peaks, MALDI-TOF MS
permits the localization of these porins and objectivizes the
loss of OmpK36 [66]. As previously reported, the infection
control consequences and particularly the risk of an epidemic
spread of the genetic support underlying a resistance trait are
associated with its mobility and its capacity to transfer from
one bacterium to another. In the present case, the genetic trait
is the truncation of the chromosomal gene that cannot be
horizontally transferred. Although it is technically reliable, this
potential application has not been included in the panel of
MALDI-TOF MS kits that are about to be marketed.
2.2.2.2. Advantages of the MALDI-TOF MS approach. The
hydrolytic activity is determined regardless of the genetic
basis of the resistance and the type of ß-lactamase. The sensi-
tivity of this technology seems to be good regardless of the
nature of the β-lactamase, including for OXA-48-like enzymes
[67]. The theoretical cost in consumables for this approach is
low (less than 0.1 euro, excluding the cost of acquiring the
machines that are now very common in clinical laboratories)
as is the cost associated with technician time. To date, the real
cost of the commercial kits remains unknown.
2.2.2.3. Pitfalls of the MALDI-TOF MS approach. A direct
comparison of the MALDI-TOF MS and Carba NP test results
highlights some discrepancies. For unresolved reasons, several
NDM- or VIM-producing Proteus spp. andMorganella spp. are not
detected by the MALDI-TOF MS approach [60]. The authors
suggested that there was a problem related to enzyme avail-
ability for the MALDI-TOF method, which did not include a cell
lysis step. Another explanation could be the type of carbapenem
compound under testing. In fact, no false-negative result was
obtained in the two other studies including M. morganii and
Providencia sp. strains, but they tested the degradation of erta-
penem or meropenem instead of imipenem [61,62]. Moreover,
for some OXA-48 variants (OXA-204) that exhibited a very low
increase in the carbapenem minimal inhibitory concentrations
(MIC), a false-negative result could be found [59]. However, the
hyperproduction of cephalosporinase could lead to a false-posi-
tive result [59]. An additional complex spectral comparison did
not improve the performance of the challenged protocol. The
standardization of the experimental conditions through themar-
keting of kits may help to solve these problems. Notably, a
positive signal when using the MALDI-TOF MS that indicates β-
lactamase activity cannot be translated into an estimation of a
MIC that might still be below the resistance breakpoint. In other
words, extrapolating whether the strain is resistant to the tested
antibiotic is not possible. However, since infection control guide-
lines are based on the presence of certain enzymes (e.g. ESBL or
carbapenemases) and preferably but not systematically to the
exact MIC value, this approach makes clinical sense. Finally, if
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using MALDI-TOF MS technology directly on positive blood cul-
tures, the same problems arise as the problems of using it for
identification purposes, including decreased sensitivity and time-
consuming pretreatment requirements. To date, using those
types of techniques for detecting multidrug-resistant strains
within a mixed flora (gut) remains impossible.
3. Antigenic rapid detection of antibiotic-resistant
Enterobacteriaceae
Recently, a new category of test wasmarketed on the basis of the
immunological detection of some specific β-lactamases as the
KPC and OXA-48 enzymes [68–70]. The performance of these
immunochromatographic tests (OXA-48/KPC K-set®, Coris
BioConcept, Gembloux, Belgium) that are easy to perform and
to interpret seems to be higher. This lateral flow immunochro-
matographic assay uses monoclonal antibodies and colloidal
gold nanoparticles bound to a nitrocellulose membrane, and it
provides results from a single colony in 15 min. Its performance
reaches 100% specificity and sensitivity, with a limit of detection
of 106 CFU/ml [69]. A recent study that employed the whole
genome sequencing approach as the reference method showed
the complete concordance between those two methods [70]. To
the best of our knowledge, no corresponding assay exists for the
detection of ESBLs, and the high diversity of enzymes that must
be detected likely prevents further developments.
3.1. Advantages of the immunological approach
Theoretically, the immunological approach could be as sensi-
tive and specific as the enzymatic approach. In fact, both
methods depend on the level of protein production, with
the immunological approach revealing the presence of this
protein and the enzymatic one revealing its biochemical activ-
ity. In published studies, these two approaches were strictly
equivalent for detecting blaKPC genes [71]; with regard to
blaOXA-48 carbapenemases, the immunological method
detected a few additional cases that were missed or that
yielded equivocal results with the enzymatic method (3 out
of 100 in the study by Dortet et al., 7 out of 130 in Glupczynski
et al.) [71,72]. The OXA-48 variants that do not possess any
significant carbapenemase activity such as OXA-163 and OXA-
405 have been reported by the manufacturers as nonreacting
variants. The small number of clinical strains (n = 3) producing
those types of enzymes that were tested in three published
studies unfortunately prevent any valid conclusions. This high
level of specificity among the large number of OXA-48 variants
is clearly a positive aspect of the immunological approach.
Some authors have tested the OXA-48K-set® directly from
spiked blood cultures (Aerobic FA Plus 30-ml bottles, BacT/
Alert system, bioMérieux, Durham, supplemented with 10 ml
of heparinized horse blood). The testing of a lysate after an 18-
h incubation time yielded excellent results [69].
3.2. Drawbacks of the immunological approach
Targeting a specific type of enzyme alone as the first step is an
approach that cannot be used as a screening test. Its price (ca.
10€ depending on the country) and the narrow panel of
available targets limit its use as a first-line strategy. It could
be of interest only in some specific settings, or in countries
with a high predominance of a single type of carbapenemase,
or during the course of an investigation of an outbreak con-
text that generates secondary cases that are presumably
related to strains that produce well-identified carbapene-
mases. Beyond the remaining doubts about the functionality
of detecting specific proteins that have been extensively
acknowledged, we must be aware of the risk of emerging
specific enzyme variants for which the targeted antigenic site
might be modified, and they consequently would not be
detected by the initially designed antibody. Regarding the
continuously increasing number of variants, a thorough mon-
itoring of the performance of these tests must be completed.
The most recent data are quite reassuring: all the OXA-48
variants with carbapenemase activity, such as OXA-181, OXA-
204, OXA-232, OXA-244, OXA-245, OXA-436, and OXA-484,
were successfully detected [70]. Nevertheless, the OXA-48K-
set® detected the naturally occurring OXA-48-like enzyme
from Shewanella spp., which is a shortcoming [70,73].
Although the prevalence of this bacterial genus in human
specimens seems to be rare, we support the presumptive
identification of suspected colonies with an oxidase test
(Shewanella spp. as an oxidase-positive bacterium as opposed
to Enterobacteriaceae) or a MALDI-TOF identification. Due to
the difference in terms of the infection control measures that
should be implemented, a positive result should be inter-
preted according to an unambiguous genus identification.
Notably, this technique cannot be used directly from clinical
specimens. In conclusion, the ICT method could be of interest
for detecting carbapenemase from isolated colonies in some
specific settings when the two targeted enzymes are highly
prevalent among carbapenemase-producing strains.
4. Recent advances in molecular diagnostics for the
rapid detection of antibiotic-resistant
Enterobacteriaceae
For two decades, molecular techniques have taken up an
increasing and now prominent place in clinical laboratories.
The primary technologies that are now implemented as rou-
tine methods are polymerase chain reaction (PCR), including
real-time PCR for the detection of pathogens and their asso-
ciated virulence or resistance genes, PCR hybridization, includ-
ing the microarray, to identify molecular sequences, and
sequencing (in particular, the so-called ‘next generation
sequencing’ (NGS)) that will likely be considered as routine
techniques within a few years. Numerous reviews have been
published recently about the contribution of nonphenotypic
and/or molecular tests.
4.1. The DNA-targeted PCR-based approach
The PCR-based approach was the earliest molecular method to
be implemented in clinical laboratories to detect ß-lactam
resistance genes among Enterobacteriaceae. Single end-point
PCRs were first described in combination with a confirmation
step using the enzymatic restriction of amplified fragments
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and/or size evaluation by agar electrophoresis, or DNA–DNA
hybridization. This multiplex process was laborious and was
subject to contamination at each step in the process. Further
improvements were implemented, such as the multiplexing
and miniaturization of the hybridization step. Real-time PCR
permitted the combination of the amplification and detection
steps in a single step, limiting the risks of environmental
contamination by amplicons. Home-made PCRs were progres-
sively replaced by commercial kits including sound protocols
and quality controls. A summary of the primary commercially
available kits is reported in Table 3. After specific multiplex
PCR amplification, the amplified DNA fragments are revealed
by hybridization with a panel of specific probes. The support
of this hybridization could be the reactive medium when
using real-time PCR or a solid surface. The number of probes
actually increases in parallel with the miniaturization of the
support, as with the microarray. The detection of resistance
genes could be performed independently, or it could be
included in multiplexed panels for the diagnosis of infections,
for example, in the context of bloodstream or respiratory
infections.
4.1.1. The whole automated real-time PCR platform: the
example of the Xpert® system
The Xpert® system is the first fully automated PCR instrument
to allow for the implementation of a PCR diagnostic method in
a very large panel of clinical laboratories. This technology
requires neither technical competency nor skilled technolo-
gists, allowing its use over a broader period during open
laboratory hours. This type of nucleic acid amplification test
might be considered as a molecular diagnostic POCT. The
different steps are performed in a single compact cassette
after the introduction of the specimen, combining DNA extrac-
tion, amplification, and revelation. An internal positive control
is included in the multiplexed targets. The Carba-R assay®
(Cepheid, Sunnyvale, CA, USA) runs on the Gen Expert® plat-
form, which is suitable for the detection and quantification of
numerous bacterial or viral species, in addition to human
tumor targets. This test is marketed to detect several carbape-
nemase genes directly from a rectal sample; a derived protocol
is provided by the manufacturer to use this assay on cultured
bacteria [95,96].
4.1.2. The Check-Direct assay®
The Check assays® (Checks points, Wageningen, The
Netherlands) include a large panel of different multiplex real-
time PCR kits using different probes, with one of them target-
ing an internal control. The DNA extraction step must be
performed outside the real-time PCR platform. The number
and type of targeted genes vary according to the kit, including
narrow- and/or broad-spectrum β-lactamase genes (see
Table 3). Different PCR platforms may be used. Although
they are thought to be cumbersome, expensive, and time-
consuming, the Check assays® are used as a reference tech-
nique to characterize β-lactamase genes from isolated colo-
nies. Recently, a new multiplex PCR panel was developed to
detect the four primary types of carbapenemase genes
directly from rectal swabs, i.e. the Check-direct CPE®
[74,77,97]. Furthermore, successful attempts to shorten the
duration of the DNA extraction step were recently pub-
lished [74].
4.1.3. Other systems
Numerous commercial systems can detect and/or confirm the
presence of resistance genes (see Table 3). They differ from
one another in their theoretical principles and their panel of
targeted genes. The most interesting features of those tests
would be their potential to identify both the bacteria and their
resistance traits as a whole, particularly in blood cultures. The
primary representative of these ‘broad-range multiplex PCR
panels’ are the Filmarray® (bioMérieux, Marcy l’Etoile,
France), the Verigene® (Nanosphere, Northbrook, US), the
ePlex® (GenMark Dx, Zug, Switzerland), the Hyplex®
superBug ID (Amplex Diagnostics GmbH, Gars-Bahnhof,
Germany), and the Unyvero® (Curetis AG, Holzgerlingen,
Germany), with the two first panels being the most widely
tested ones. Regarding the Xpert® system, these PCR panels
do not require extended skills and could theoretically be used
24 h per day. Interestingly, some assays seem to be valuable
for the detection of resistant genes in other clinical specimens
of high interest to diagnose respiratory, urinary tract, or joint
infections due to resistant bacteria [82,86,98]. Regarding
bloodstream infections, some of these assays could be positive
earlier in comparison to blood culture systems [83]. Beyond
their analytical performance, the adequacy of the targeted
gene panel for local epidemiology and their costs (approxi-
mately 150 euros per test) are still considered as a limitation to
their development (see later).
Other assays have been developed to characterize the β-
lactamase content of a given isolate to decrease the cost and
improve the detection of multiple allele variants in a single
isolate. The Luminex ® (Luminex Corporation, Austin, TX, USA)
technology is a well-established detection approach that relies
on colored microsphere-based flow cytometry assays. This test
allows for the detection of specific alleles, antibodies, or pep-
tides, and it has been already marketed for other purposes
such as HLA typing, seroprevalence studies, or the detection
of a broad panel of microorganisms directly from clinical
specimens such as stools. Recently, a Luminex xTAG® assay
was developed to detect ESBLs, plasmid-mediated cephalos-
porinases, and carbapenemases [94]. The modular multiplex
oligonucleotide ligation-PCR procedure allows for the detec-
tion of β-lactamase genes and their variants for less than 5
euros per sample and a TAT of 5 h. Regarding the first pub-
lished study, the sensitivity and specificity are excellent (100%
and 99.4%); the different variants of the same β-lactamase
genes (as blaTEM) present in the same isolate could be sepa-
rated. The subtyping of the blaCTX-M gene is also performed.
Additional data are required, but this approach seems to be
promising.
4.1.4. Performance
4.1.4.1. Sensitivity. The performance of the molecular meth-
ods, and particularly the commercial multiplexed PCR assays,
must be considered in view of different clinical or technical
settings. The most favorable setting is the characterization of
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the β-lactamase content of bacterial cultures, and the most
difficult setting is the detection of resistance genes in a highly
diverse and DNA-rich environment such as the gut flora.
4.1.4.1.1. Sensitivity with pure bacterial cultures. In this case,
the sensitivity of the assay relies only on the size of the
targeted gene panel and not on the quantity of available
DNA material. According to the increasing number of targets,
including in the most recent commercial kits, the performance
is excellent. For example, the Check-MDR CT103 XL array is a
new product that allows for the amplification and identifica-
tion of a large panel of β-lactamases, including ESBLs, cepha-
losporinases, and carbapenemases. Its sensitivity against a
sample of 223 strains was 100% [79]. Moreover, the commer-
cial assays include an internal control that detects the pre-
sence of Taq polymerase inhibitors.
4.1.4.2. Sensitivity with clinical specimens
4.1.4.2.1. Clinical specimens with poor bacterial diversity
(positive blood culture, urine). The sensitivity of β-lactamase
gene detection directly from clinical specimens such as urines
or positive blood cultures, with blood culture being an ‘artifi-
cially boosted’ clinical specimen, relies solely on the correla-
tion between the targeted genes and the local
epidemiological setting. For example, the FilmArray® blood
culture identification panel that targets only the blaKPC carba-
penemase gene could be of interest in areas where this gene
is highly prevalent (Italy, Greece, etc.). Frequently, assays tar-
geting the clinical specimen mix the identification of the
causative bacteria and the most relevant associated resistance
genes. This tendency could at least decrease the possibility of
multiplexing the resistance genes for technical limitations.
However, in considering the culture as the reference techni-
que, the performances of those molecular tests are excellent if
the resistance gene is included in the test panel, with the
sensitivity being 100% [97]. Comparative studies basically
showed similar and excellent performances for the different
commercial kits [80].
4.1.4.2.2. Clinical specimens with a high diversity of bacteria
(stools, rectal swabs). Compared to the culture-based
method, the performance of molecular methods, and particu-
larly their respective sensitivities, is still a matter of debate. In
fact, the culture-based method is considered the gold stan-
dard in terms of sensitivity, especially if combined with a pre-
enrichment step. Recently, data that were provided about NGS
technologies, particularly shotgun metagenome sequencing,
question the validity of culture-based techniques as the gold
standard [99, see discussion also later].
The detection limit of culture-based approaches for ESBL-
producing or carbapenem-resistant Enterobacteriaceae in pure
culture when using the best selective plates is approximately
10 CFU/ml [93,100].
Performance characteristics from molecular methods vary
significantly according to the type of assay; the limits of
detection for clinical specimens vary from 10 CFU/ml to
1,000 CFU/ml [78,93]. Global performance should be adjusted
to the bacterial DNA extraction rate, which may vary according
to the nature of the strain, the putative inhibitory properties of
some specimens (stool, blood, etc.), and the number of resis-
tance genes. Some home-made real-time PCR assays reach
performances as high as those of culture-based methods,
with detection limits evaluated at 100 CFU/ml of feces. In
some cases, the molecular method is 10- to 100-fold more
sensitive than the culture-based strategy [77,93,101,102]. The
significance and interpretation of a molecular positive-culture
negative screening test still constitutes a challenge to clinical
microbiology [77,78,97]. Overall, a home-made PCR targeting a
single β-lactamase seems to be more sensitive than multi-
plexed commercial assays; the competitive and technical
requirements for administrative agreement lead to increased
values in the limits of detection [93].
Several studies have reported suboptimal sensitivities when
dealing with mixed gram-negative blood cultures, or when a
single strain carried several resistance genes [80,103]. Beyond
the previously reported difficulties in including all the variants
of a large family of β-lactamases, for example, in blaCTX-M,
competition may occur when different targets must be ampli-
fied from the same specimen [80]. This pitfall may lead to
false-negative results and could have clinical consequences.
Obviously, the risk of false detection results for polymicrobial
specimens is shared by the different methods (culture, bio-
chemical testing, MALDI-TOF analysis, and molecular screen-
ing). Microbiologists should modulate their confidence in the
results according to the nature of the specimen, whether it is a
pure subcultured isolate, primoculture, or noncultured clinical
specimen. Some recent assays seem to solve this issue, such as
the Luminex ® assay [94].
4.1.4.3. Specificity
4.1.4.3.1. Specificity for pure culture. Once the panel is suffi-
ciently large and adapted to local epidemiology, the real
remaining challenge for molecular methods is the specificity,
or the capacity of an assay to separate the natural chromoso-
mally or plasmid-encoded narrow-spectrum β-lactamases from
the extended-spectrum, acquired ones. This issue is well
established for cephalosporinase coding genes such as
blaAmpC, blaACC, or blaDHA and constitutes a challenge for
some molecular methods [104]. Moreover, among the variety
of β-lactamases identified in Enterobacteriaceae, a high num-
ber of variants from the same class have sometimes been
described; for example, more than 300 members of OXA
enzymes have been reported. In some cases, and as noted
earlier for OXA-48 variants, the acquisition of a single or few
mutations may instead lead to an expanded or narrowed
hydrolytic activity [87]. This phenomenon is also known in
ESBLs that are derived from their narrow spectrum counter-
parts in the TEM and SHV families. This issue definitely con-
stitutes a real challenge for the design of specific primers and
probes [80]. For example, the Check-ESBL assay (Check-Points
Health) correctly differentiates among the narrow-spectrum
blaTEM and blaSHV-encoding genes from the variants that
encode ESBLs. However, the same technology fails to distin-
guish some acquired and plasmid-borne blaAmpC genes from
their intrinsic and chromosomally encoded counterparts. This
challenge was clearly addressed by the most recent assays
[79,94]. For some assays, the subtyping of the β-lactamase is
available, as it is for the blaCTX-M families [94]. Unfortunately,
the detection of overexpressed natural enzymes through a
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mutation in the regulator genes, as is the case for blaAmpC,
could not be detected without a sequencing approach.
4.1.4.3.2. Specificity for clinical specimens. The vast majority
of the PCR methods identify their targets (the genes) without
identifying the surrounding genetic environment. This draw-
back was previously reported with MRSA and the confounding
coinfection or co-colonization with methicillin-resistant coagu-
lase-negative Staphylococci and methicillin-susceptible S. aur-
eus. Additional targeted genes have been shown to
overwhelm these pitfalls, for example, in the Xpert® MRSA/
SA BC or SSTI that included an additional target corresponding
to the junction between the staphylococcal cassette chromo-
some mec gene (SSCmec) and the part of the S. aureus genome
where the SSCmec is supposed to be inserted, namely the
SCCmec-orfX junction. Furthermore, the detection of a gene
without phenotypic correspondence constitutes a well-known
pitfall of DNA-based strategies [81]. Combined with low pre-
valence for the targets, the positive predictive value of the
molecular test may dramatically decrease to as low as 5–10%
[17]. This drawback is particularly relevant when rich micro-
biota, such as that of the digestive tract, is screened for CPE.
As previously described for the immunological methods, this
type of pitfall has been identified recently for the detection of
ß-lactamase genes as follows: nonpathogenic Shewanella spe-
cies harboring a blaOXA-48-like gene (its natural progenitor) led
to a false-positive molecular result in a patient with a history
of blaOXA-48 K. pneumoniae [73]. Moreover, the increasing pre-
valence of nonfermentative gram-negative bacteria harboring
carbapenemase genes such as blaVIM-positive P. aeruginosa is
a source of confounding results when a screening program is
implemented for infection control purposes [105]. Thus, in a
large screening cohort of 3644 patients and 16,296 samples,
the number of positive CPE patients was low (n = 43), and 4
patients carried a VIM-positive P. aeruginosa. Ten percent (4/
43) of patients were initially and falsely identified as CPE-
positive, leading to confounding isolating measures and mes-
sages toward patients, their families, and health-care workers
[106]. Moreover, the positive predictive value of the screening
was only 86% [106]. A lower positive predictive value of 50%
for the screening was reported by Simnet et al., with PCR-
positive culture-negative cases exhibiting mostly high thresh-
old cycle values (CT >39) [107]. The authors suspected low-
level colonization below the limit of detection for the culture-
based screening method or nonspecific signal. This finding
contrasts with in vitro studies that support a higher sensitivity
in bacterial culture. Regarding the clinical specimen that
required a semiquantitative interpretation of the cultures, for
instance, the respiratory tract specimens, the cut-off loads (103
for a protected distal specimen, 104 for a bronchoalveolar
specimen, and 106 for sputum) are significantly higher than
the limits of detection for the molecular method. This differ-
ence leads to confusing discrepancies [104]. Nevertheless, the
follow-up of these PCR-positive-culture-negative patients is
questionable (see later).
4.2. The RNA-targeted molecular approach
One of the primary disadvantages of the DNA-targeted
approach corresponds to a lack of differentiation between
silent and expressed genes or between dead and living bac-
teria [81]. The replacement of DNA by RNA targets overcomes
this problem and diminishes the putative gaps between
genetic and phenotypic results. One manufacturer has devel-
oped a kit for the detection of blaKPC variants (NucliSENS
EasyQKPC test®, bioMérieux), and its TAT is 2 h [108].
4.3. The PCR electrospray ionization mass spectrometry
(PCR/ESI MS) approach
This technology is based on the ability of some very powerful
mass spectrometry instruments to accurately measure the
exact molecular masses of small PCR products at less than
500 bp [109]. After that, advanced software reconstructs the
sequence of the DNA fragments, allowing for their accurate
identification. Given the example of the former Septifast®
assay (Roche Diagnostics, Basel, Switzerland), these
approaches do not require a culture step, and they are time-
and cost-effective. A fully automated system is also available
(PLEX-ID; Abbott Bioscience), with the corresponding first-pub-
lished data about bacterial identifications being quite
encouraging, and the TAT from clinical samples being 4–6 h.
Preliminary results for resistance gene analysis support the use
of this technology to identify the blaKPC genes [110].
Nevertheless, the cost of the system (ca. 200,000 USD) remains
prohibitively high for a large majority of clinical laboratories.
4.4. The clinical impact of the molecular approach
4.4.1. The individual impact
Beyond theoretical and intermediary results such as the TAT,
the cost savings, and the delayed optimization of antimicro-
bial therapy, the impact of molecular methods on the clinical
outcome is poorly established. A recent review and meta-
analysis showed that (i) there was a relatively low number of
studies pertaining to clinical outcomes, (ii) the one combined
cohort showing a significant reduction in mortality when rapid
molecular testing is associated with direct communication,
and (iii) there was a lack of significant impact on mortality
for rapid phenotypic techniques associated with direct com-
munication [6]. More specifically, the molecular assay was a
peptide nucleic acid fluorescent in situ hybridization that was
performed directly on a positive blood culture in comparison
with a Gram stain, and the phenotypic approaches that failed
to reduce the mortality consisted of rapid antimicrobial sus-
ceptibility testing with Vitek ® (bioMérieux, Marcy l’Etoile,
France) or Microscan ® (Beckman Coulter, Sacramento,
CA, USA).
4.4.2. The collective impact
Although it seems like common sense, the impact of
decreased antibiotic pressure in response to a rapid molecular
testing strategy was not established. Moreover, the impact of
this approach in terms of infection control, i.e. the decrease of
the occurrence or the duration of outbreaks has not been
concluded; an intermediate positive impact such as the time
until contact isolation has nonetheless been reported [111].
13
htt
p:/
/do
c.r
ero
.ch
4.5. Advantages of the molecular-based approach
Compared to biochemical and immunologic approaches, the
primary advantage of the molecular-based approach is its capa-
city to be used directly from complex clinical specimens includ-
ing rectal swabs and stools. The current trend is the development
of multiplexed real-time PCR that allows for the detection of
different relevant targeted genes leading to the identification
of the causative agents and the primary frequently acquired
resistance genes. This approach rapidly provides critical data
about natural and acquired resistance traits. This information is
of paramount importance for clinical decision-making, especially
for life-threatening infections. The total hands-on time from the
arrival of the specimen to the test result actually varies, but it
does not exceed 1 h, as opposed to a median time of 2 or 3 days
when using conventional methodologies requiring the culture of
the specimen on a selective medium followed by antimicrobial
susceptibility testing. The ability of some of these tests to be
implemented as POCT will surely improve their availability and
TAT. If they are available in clinics, those tests can offer an
accurate diagnosis beyond laboratory open hours and/or
decrease the turnaround time in limiting the transport delay
from the clinical ward to the laboratory.
The low level of resistance conferred by some genes some-
times leads to a lack of phenotypic detection. However, a
clinically significant level of resistance may appear under anti-
biotic selective pressure, which has been reported for VRE [112].
In this particular case, the molecular detection of the genes
clearly provides an advantage. When considering β-lactamase
detection, some enzymes do confer a low level of resistance. As
an example, some OXA-48-producing enterobacterial isolates
do exhibit a low level of carbapenem resistance that could
escape phenotypic detection. In fact, the MICs of carbapenems
from some OXA-48-like producers may be ca. 0.25–0.5 mg/l,
which are below the cut-off limits for determining carbapenem
resistance. Due to the high transmission rate of the epidemic
plasmid bearing the blaOXA-48 gene, the level of resistance could
be significantly increased if the plasmid is transferred in another
strain possessing another background that might exacerbate
the resistance trait, giving rise to much higher MICs. Regarding
infection control, molecular tests can be performed directly in
complex microbial communities, including stools or rectal
swabs. If combined with bacterial identification, the molecular
panels constitute an efficient test to help clinicians to rapidly
implement the most appropriate antimicrobial strategy. As a
surrogate method for DNA sequencing, the PCR/ESI MS method
distinguishes among single nuclear polymorphisms and allows
for the fine subtyping of the resistance gene.
Notably, the fact that molecular methods may either detect
viable or nonviable microorganisms may be considered as
either an advantage (higher sensitivity) or a disadvantage
(for having a lack of significant clinical relevance).
4.6. Drawbacks of the molecular approaches
4.6.1. The limited number of targeted genes; walking in a
moving landscape
As previously reported, the evolving diversity of β-lactamase
genes constitutes a challenge when addressing specific
methods such as gene-targeted PCR. The multiplexing capa-
city of commercial kits is limited. The choice of the gene panel
depends on which ones are considered or defined to be the
most relevant in a given geographical area and within a given
period of time [111]. Numerous commercial kits were devel-
oped for the U.S. market, with focus on the blaKPC gene, which
is the most prevalent carbapenemase gene in this area; unfor-
tunately, assays such as the FilmArray Bloodculture
Identification® panel have stirred little interest in the geogra-
phical area where other carbapenemase genes are more pre-
valent. Likewise, the first Cepheid panel, namely the Xpert
MDRO assay®, did not include the blaOXA-48 that was not
prevalent in the U.S. [113]. Recently, this gene has been
included in the cartridge and the kit that was renamed Xpert
Carba-R®. However, failures to detect producers of OXA-48
variants, such as OXA-181 [75,114,115], have been reported.
An updated version of the test had to be developed that
encompasses the blaOXA-181 and blaOXA-232 variants [76]. The
molecular approaches are challenged with OXA-48 enzymes
since the corresponding genes encompass many variants [87].
One consequent problematic issue may be the nonrecognition
of some variants on one hand and the recognition of variants
that exhibit different hydrolytic properties on the other hand.
In recognizing the hydrolytic variants, molecular assays do not
differentiate between a blaOXA-48 gene encoding a ß-lacta-
mase-hydrolyzing carbapenem, but they do spare expanded-
spectrum cephalosporins and a blaOXA-163 gene encoding a ß-
lactamase sparing carbapenems; conversely, they hydrolyze
expanded-spectrum cephalosporins. As previously described,
some microarray assays combine a very large panel of tar-
geted genes; nevertheless the cost, dedicated materials, and
TAT could limit their use [79]. Some technical solutions com-
bine the PCR amplification of a large number of targets fol-
lowed by a new generation of sequencing (see Section 4.4.1).
Beyond the diversity of genes, the inability to detect a new
(possibly emerging) gene constitutes a major limitation in the
molecular approach. As an example, the recently identified
class A carbapenemase FRI-1 that was recovered from an
Enterobacter cloacae isolate is not recognized by any available
molecular kit on the market [116]. This finding has also been
demonstrated for other bacterial species such as in
Staphylococcus aureus with the under-recognition of the emer-
ging mecC gene among methicillin-resistant S. aureus [87]. The
changing epidemiology of the β-lactamase-encoding genes
will surely remain a challenge for industry and for clinical
laboratories. To complicate this issue further, the time
required to modify a commercial test usually exceeds 1 year.
Thus, one of the remaining issues is the predictive negative
value of a negative test. If the targeted gene was previously
identified (e.g. for a contact patient) and was included in the
panel, this value is high and leads to a univocal decision.
Conversely, a negative result for the first screening of an
unknown patient or the typing of an unanticipated resistant
strain should be interpreted according to the adequacy
between the epidemiology in the resistance supports of
patient origin and the panel of the assay. Obviously in this
case, especially when the patient comes from a distant coun-
try in which the epidemiology of resistance genes is poorly
understood, the interpretation of a negative result depends of
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the clinical severity (if it guides the choice of an empirical
therapy) or the care volume and risk of transmission (if it
guides the choice of the infection control measures).
4.6.2. The reasons and consequences for discordant/false
results
4.6.2.1. Discordant results. Discordant results raise a ques-
tion about the gold standard technique that should be con-
sidered during pathogen detection. We have reported some
factors that are associated with lower sensitivity in the mole-
cular methods. The culture-negative molecular testing-posi-
tive-discordant cases could range from 5% to 55% [77]. As a
result of the increasing sensitivity of the most recent molecu-
lar assays, including the next genome sequencing (NGS)
approach, the culture-based method could miss antibiotic-
resistant bacteria if they had a low inoculum. For example, in
Lau et al., the molecular method was 10-fold more sensitive
that the culture-based method for two K. pneumoniae strains
carrying blaOXA-48 and blaOXA-244 genes [77].
Beyond the possible lack of sensitivity of the culture meth-
ods, several other explanations could be proposed as follows:
● the presence of additional nontargeted bacteria in the
specimen (non-enterobacterial gram-negative bacteria
such as P. aeruginosa or Shewanella sp.) that carried the
targeted resistance gene, as found, for instance, for blaOXA-
48, blaVIM or blaKPC, and that are not detected by culturing;
● the presence of dead or noncultivable bacteria: one of
the five discordant patients in the study by Antonelli
et al. had a history of KPC-producing K. pneumoniae
colonization [78];
● the presence of bacteria that harbor but do not express
the targeted resistant gene, as in the intrinsic blaOXA-51
from A. baumannii that is responsible for carbapenem
resistance, only if a strong promoter is provided by the
insertion of the insertion sequence ISAba1. This issue
may be solved by focusing on RNA rather than DNA
detection; and
● the presence of bacteria that harbor the targeted resis-
tant gene but express it at a very low level, and the use
of selective culture plates with predefined antibiotic con-
centrations could lead to the false-negative screening of
a culture.
4.6.2.2. Clinical consequences of discordant results. For
clinical care, the very serious error of a false-negative result
could lead to inappropriate therapy and a putatively pejora-
tive outcome. Nevertheless, if the false-negative result is due
to a nonexpressing gene or a very low level of phenotypic
resistance, then the clinical consequences should be limited.
For instance, the presence of a gene that codes for a carba-
penemase may not exclude the carbapenem from the thera-
peutic choice. In fact, patients infected by a CPE (VIM
producer) for which the meropenem MIC was ≤4 mg/l might
benefit from carbapenem therapy, at least in combination
[117]. Beyond carbapenem therapy, the detection of a carba-
penemase gene could nonetheless encourage clinicians to
prescribe a combination therapy. However, a false-positive
test (i.e., a major error) could lead to an unnecessarily broad
spectrum empirical therapy that would then lead to the selec-
tion of resistant strains.
4.6.3. The impact of the culture-independent diagnostic
assays on the survey study
For other public health domains, the development of culture-
independent diagnostic tests raises questions about its impact
on surveillance studies [118]. We believe that culture-based
methods remain necessary for the following reasons: (i) the
need to compare the strains that are responsible for outbreaks
and (ii) the lack of absolute parallelism between the presence
of a gene and the occurrence of resistance. Clinical isolates
usually express combined mechanisms of resistance that will
be difficult to show by using molecular techniques, including
whole genome sequencing. One of the good examples corre-
sponds to the overexpression of efflux proteins and decreased
outer membrane permeability in the P. aeruginosa species that
may lead to multidrug resistance but cannot be identified by
molecular methods.
4.6.4. The cost
Molecular methods remain more expensive that biochemical
tests (from 30 to 60 USD vs. 5 to 10 USD). Nevertheless, this
cost must be balanced against the TAT and the technical
time (Table 4). This cost increases when invalid/inhibited
samples were identified. The percentage of unresolved sam-
ples that required retesting after, for example, a freeze–thaw
cycle, is scarcely reported, but it could reach 3.2% of the
total sample number [78]. Sometimes, a second testing step
is still insufficient for obtaining an informative result. In Lau
et al., 52% of the invalid samples could not be resolved even
after additional testing [77]. Pooling the test specimens to
minimize the overall cost significantly decreases the detec-
tion rate if the inoculum of the targeted gene is originally
low in one of the specimens (e.g. 150 CFU per swab) [77].
The development of home-made techniques may result in
Table 4. Comparative advantages and disadvantages of molecular versus bio-
chemical rapid tests from the individual and public health perspective.
Molecular
tests Biochemical tests
Applicable directly on clinical
specimen
Yes Yes (urines and blood)
Necessity of viable organisms No Yes
Broad range screening No Yes
Nonspecific or nonconclusive result No Yes
Discover of new resistance
mechanism
No Yes
Technically skill requirement +* No
‘Hands-on’ technical time Variable Low
Turnaround time 1 to 2 h From 2 min if positive
to 2.5 h if negative
Cost per test 23–150 USD 2–10 USD
Detection of low-level resistance Yes Yes
Detection of cryptic resistance
gene
Yes No
Special equipment requirement Yes No
Additional testing required for
definitive identification
No Yes
*Except Cepheid.
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cheaper costs, but those techniques may not correspond to
modern requirements.
5. Future approaches
5.1. The NGS approach: determining the ‘resistome’
5.1.1. Principles of the NGS approach
Next to the PCR revolution in the early 1990s, NGS technology
is changing the field of microbiology. The NGS technology is a
high-throughput sequencing method that allows for the con-
comitant determination of the nucleic acid contents of thou-
sands or millions of genes [109]. It can determine the
complete genome of a cultivated bacterium in only a few
days instead of several months. The contribution of this
‘Whole Genome Sequencing (WGS)’ approach was demon-
strated during an outbreak of enterohemorrhagic E. coli in
Germany in 2011. NGS technologies aid in understanding
pathogenesis and identifying resistance genes, developing
diagnostic tools, and improving patient care [119].
Interestingly, this strain carried a blaCTX-M-15 ESBL that was
characterized because of the WGS data analysis. Next to the
WGS approach, the NGS technologies help researchers to
explore the microbiome; the metagenomic analysis of a speci-
men consisted of sequencing its entire DNA content from all
the cultivated and uncultivated bacteria. This analysis could be
focused on 16S RNA gene sequencing by using a PCR
approach (‘16S rRNA metagenome sequencing’ or ‘metage-
nomics’), allowing an identification at the genus and some-
times species levels of the different bacteria present in a
specimen. More interestingly, the ‘shotgun metagenome
sequencing’ approach allows for the sequencing of the
whole DNA extract from an uncultivated specimen, and it is
not limited to 16S RNA gene sequencing. Beyond a more
accurate bacterial identification, this approach enables inves-
tigators to highlight the presence of resistance or virulence
genes without the need for a culturing step. Nevertheless, the
difficulties associated with the manipulation and interpreta-
tion of important amounts of data have now replaced the
technical issues (see later). Finally, the sequencing of the
whole mRNA pool of a strain or a specimen helps in capturing
the image of all the genes that are expressed at a given time
(‘the transcriptomics’) [99].
The technical specifications for the different methods used
for WGS were out of the scope of this review article and have
been discussed before [109,120]. In brief, since the end of 454
technology (Roche Diagnostics, Basel, Switzerland), several
instruments have been made available, with each of them
having their pros and cons. Next to Illumina technology (San
Diego, CA, U.S.A.), the Ion Torrent semiconductor sequencing
(ThermoFisher Scientific, MA, U.S.A.) and Pacific Biosciences
(CA, U.S.A.) platforms bring alternative solutions, with the
Pacific Biosciences product generating very long reads that
facilitate de novo assembly (see later) [109,120]. To constitute a
real revolution that can be implemented within clinical micro-
biology, a new technology has to be available for the majority
of scientists, including clinical microbiologists. The following
two primary features of the NGS revolution reach this goal: (i)
the miniaturization of the instruments, with the marketing of
bench machines such as the previously produced 454 Junior
and the MiSeq and Ion Torrent instruments, and the still-
under-assessment ultra-miniaturized MinION MkI (Oxford
Nanopore, Oxford, U.K.) and (ii) the decreasing cost of the
process allows for the sequence of a whole genome for less
than 150 euros [119]. In parallel, the availability of commercial
software in the pipeline to sort out and classify the huge
amount of sequencing data and user-friendly websites to
identify genes of interest will definitively place WGS at the
center of clinical laboratories in the near future.
Regarding antimicrobial resistance, the NGS technologies
could improve the detection and characterization of the
mechanisms and the genetic support and background in
terms of accuracy and rapidity [119]. Beyond pyrosequencing,
which has been shown to be useful in differentiating the
variants of a core resistance gene [121,122], the NGS approach
allows for the determination of the whole genome of a bac-
terium that could be subsequently challenged against a data-
base that contains a list of resistance genes [119]. It was
initially developed for culture-pure isolates, and this technol-
ogy was then extended to clinical specimens that contain only
one bacterial species in sufficient quantity (urine) and then
more complex specimens such as stools or respiratory tract
specimens. The use of the NGS in such complex environments
highlights the critical issue of (i) DNA extraction from different
bacterial populations and (ii) the technical and in silico clean-
ing of human DNA. The NGS approach leads to the identifica-
tion of the resistome from a strain or a microbiome, that is, the
pool of genes implicated in the natural and acquired antimi-
crobial resistance in bacteria.
5.1.2. The resistome, a surrogate for the phenotypic and
molecular characterization of resistance?
Accessing the resistome of bacteria allows researchers to
answer the questions in this review in a theoretical sense.
Several publications reported high consistency between WGS
data and antimicrobial susceptibility testing results among
Enterobacteriaceae, especially E. coli, K. pneumoniae, and
Salmonella sp [123–126]. The correlation between the WGS-
based resistant gene armamentarium of a bacterium and its
phenotypic antibiotic susceptibility appears to be as high as
99%, reaching the error rate targets of the U.S. FDA for market-
ing approval (<1.5% very major discrepancy rate and <3%
major discrepancy rate). User-friendly bioinformatics
approaches such as the ResFinder® website from the Center
for Genomic Epidemiology are now available, with some for
free and some other requiring an additional payment for use
[99,102,127]. After the production of raw data by the NGS
instruments (‘reads’), bioinformatics processing could be per-
formed directly or after being assembled into consensus
sequences (‘contigs’). A trimming step has to be performed
in silico to clear the biased reads from the data set (see later).
In focusing on β-lactam resistance, the following challenges
should be addressed: (i) the detection of acquired genes, (ii)
among them the separation of narrow- and broad-spectrum β-
lactamases that differ by point mutations, and (iii) the detec-
tion of mutations/deletions in natural genes and/or in promo-
ter regions that could lead to acquired resistance. Obviously,
this last class of genetic events is difficult to detect, requiring
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high accuracy for single-nucleotide polymorphism (‘SNP’)
identification and large contigs to obtain the upstream
sequence of a putative resistance gene.
To address the putative clinical implications of an exclusive
in silico approach, a new committee from the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
was created in 2015, which was called the ‘EUCAST subcom-
mittee of the role of WGS in antimicrobial susceptibility testing
of bacteria’ (http://www.eucast.org/organization/subcommit
tees/). The first reports from this committee are pending.
Moreover, the NGS approach has been shown to be effec-
tive for detecting MDR bacteria from a whole microbiome. In
light of the most recent data collected by shotgun metagen-
ome sequencing, the assignment of the gold standard label
to culture-based methods could be questioned. In the work
of Andersen et al., half the inpatients experienced coloniza-
tion with an MDR bacterium that was not identified by
culture but was highlighted by fecal metagenome sequen-
cing [99].
5.1.3. Advantages of the NGS approach
The NGS approach displayed several advantages compared to
the culture methods or targeted molecular assay. First, the
NGS may characterize pathogens that cannot be cultured
because of inappropriate growth conditions or previous anti-
microbial treatment. Moreover, unlike the targeted molecular
assay, the NGS approach could detect mutations or resistance
genes at extremely low levels in a bacterial population. This
capacity leads to the designation of the ‘ultra-deep
sequencing’ concept that allows researchers to identify the
presence of mutants at a level of less than 1% of the popula-
tion. Nevertheless, this approach requires high coverage (i.e. a
number of sequencing products) of the relevant zone of the
genome (more than 10,000-fold) through an initial specific
PCR-based amplification step. This approach was successfully
implemented in the virology domain to detect minor popula-
tions of mutants among HIV or HBV/HCV populations. The
presence of these mutants could predict the clinical success
of an antiviral regimen. This approach could be implemented
to target the hot spots of mutations among bacterial gen-
omes, detecting some genetic backgrounds that could lead to
the emergence of resistant subpopulations in some specific
clinical settings (high inoculum, presence of exogenous mate-
rial, immunosuppressed status of the patient, long-term anti-
microbial therapy, etc.). In comparison to targeted molecular
methods, the WGS could also detect some new β-lactamases
or new mutations in known genes as reported in the work of
Kos and colleagues, who were interested in the resistome of P.
aeruginosa [128]. Beyond the acquisition of new genes, the
putative difficulty in detecting the overexpression of chromo-
somal β-lacatamase as AmpC could be overcome. For exam-
ple, in a study by Tyson et al., the cefoxitin resistance of three
E. coli strains that did not show any other resistance mechan-
isms was explained by the detection of a mutation in the
ampC promoter [125].
Beyond the resistome, the WGS of a given strain allows
access to its whole genetic heritage, including virulence gene
identification, phylogenetic tree building, the localization of
mobile genetic elements that may support the resistance
genes such as plasmids, phages and integrons, genetic back-
ground characterization (such as MLST typing), and outbreak
investigation using SNP quantification [125,128]. These addi-
tional data are available without extra charges, requiring only
the in silico analysis of the genome. Sometimes, all these
possibilities are available at the same website (e.g. the
Center for Genomic Epidemiology, http://www.genomicepide
miology.org/).
5.2. Pitfalls of the WGS approach
As previously reported, the availability and cost of WGS tech-
nology should not be a hurdle in the near future. The delay
required for data production, which was a limitation for clin-
ical purposes, decreases in parallel to the decrease in cost and
the increase in indications. At present, the sequencing and
bioinformatics process could be performed with a three-day
delay that is competitive with the culture approach, but not
with targeted molecular methods that do not require addi-
tional sequencing. Some technical limitations of each type of
NGS instrumentation have been clearly identified. For exam-
ple, the pyrosequencing method used in the 454 instrumenta-
tion and the semiconductor sequencing used by the Ion
Torrent system fail to generate reliable sequences of homo-
polymers higher than 4 or 6 nucleotides in length, respec-
tively. These drawbacks could be managed by combining
different technologies to confirm or correct the sequencing
of some particular regions of the genome. Nevertheless, this
solution increases the final cost of sequencing.
To date, the primary limitation of the NGS approach has
clearly been the bottleneck that occurs during the interpreta-
tion of this huge quantity of data for gene identification and
phenotypic transcription. If single gene characterization can
be performed easily using available databases, then the inter-
pretation of the results has been previously reported to be
performed with caution [128]. Some drawbacks still persist
such as the quality of the reference database or the para-
meters used to produce and compare sequences. The results
of the in silico analysis could differ according to the software
and database [126,129]. For microbiologists who are not
skilled in bioinformatics technologies, the different software
types that are provided by instrument manufacturers and
web-based platforms constitute some type of ‘black box’. For
example, the de novo assembly step that leads to the building
of contigs without a reference strain could lead to the loss of
information; in fact, if a resistance gene is spread over two
contigs, it may not be detected even though the coverage cut-
off is lowered (60% for the ResFinder software) [126]. The use
of reads without an assembling step should be of interest
[126]. For clinical applications, the lack of control over this
part of the analysis by biologists clearly constitutes a draw-
back. Notably, the databases should be regularly updated to
include new resistance genes or mutations [129]. If a database
is free of charge for users, its durability might be compromised
if financial support fails. Obviously, the majority of the well-
designed studies that are published have relied at least in part
on ‘home-made pipelines’; these approaches require bioinfor-
matics skill and cannot be translated in clinical laboratories. As
times change, some scripts using the Perl or Python languages
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are now available as supplementary data in nonspecialized
journals. Some commercial solutions are under development
to include the NGS technology in commercial in vitro diagnos-
tic CE-marked systems to improve the performance of the
targeted PCR approach, such as the Pathogenica HAI
BioDetection system (Pathogenica Inc., Boston, MA, U.S.A.)
[130]. Regarding the metagenomic shotgun approach that
could provide the Holy Grail in terms of detecting resistance
genes from clinical specimens, the technology currently pre-
sents some drawbacks as follows: a huge amount of data to
produce, analyze, and save; the need for bioinformatics and
statistical skills; and so far a statistical association between
resistance genes and bacterial species that leads to ‘MDR
potential’ rather than the definitive characterization of the
whole genome of an MDR bacterium [99]. However, in light
of the complexity of the MDR carriage and particularly the
within-host diversity, the culture method could be considered
as an excessively simple solution for a complex issue [131].
As previously reported, the detection of resistance traits
based on mutations in promoters or the coding regions of
natural genes are more difficult to detect than exogenous
genes. Mutational events linked to blaAmpC overexpression
have been properly identified in several published works.
However, β-lactam resistance due to mutations in porins, as
in imipenem-resistant P. aeruginosa, or insertion sequences
that provide a strong promoter, as in Bacteroides sp., should
be improved, requiring high resolution and/or complete gen-
ome sequencing [132]. In a study by Kos et al., the genetic
support of the meropenem resistance was not identified in 15/
154 P. aeruginosa; additionally, the quality of the OprD
sequencing was insufficient for eight isolates to predict the
meropenem susceptibility in silico [128]. The insufficient qual-
ity of the sequencing, i.e. the high number of contigs or the
low coverage of some genomic regions, could limit the per-
formance of the method. Thus, the detection of the genetic
support such as the integrons or plasmids could be incom-
plete or inconclusive. Some software that allows for the detec-
tion of plasmids from raw sequencing data is available, such as
Plasmifinder. This free tool detects replicons using a curated
database, identifying the part of the genome that could be
part of a plasmid [133] The website also subtypes the identi-
fied plasmids according to a plasmid MLST analysis.
Nevertheless, the comprehensive characterization of the larger
plasmids still requires the extraction, separation, and indivi-
dual sequencing of each plasmid unless the selected technol-
ogy provides very long reads, such as the use of PacBio®
instrumentation.
Moreover, some complex supports of resistance that
involve cooperation between several genes and associated
regulators are probably more difficult to identify than
mechanisms based on the presence/absence of a resistance
gene. For instance, the results of the resistome approach could
vary according to the nature of the given mechanisms. Kos
et al. sequenced 390 strains of P. aeruginosa from various parts
of the world, and they found that the consistency between
their culture-based susceptibility data and the resistome was
lower for aminoglycoside resistance, implying more gene
expression variations than for ß-lactam resistance, such as for
meropenem resistance (60% vs. 91%, respectively) [128].
A large number of these pitfalls could be fixed by improv-
ing the quality of the sequencing process. To date, the best
solutions have combined technologies that provide very long
reads such as the PacBio® instrumentation to build the scaf-
fold of the genome and the putative plasmids, and high
coverage methods such as the Illumina® approach.
Nevertheless, this combination increases the cost and the
time needed to interpret the data. Supplementary technical
approaches such as transcriptome analysis using RNA-seq or
microarray gene expression could overcome the issues asso-
ciated with gene expression and regulation, especially for
some bacterial species. Antimicrobial compound combinations
such as P. aeruginosa/meropenem provided insufficient corre-
lations between the presence of a gene and its phenotypic
resistance. In fact, this transcriptome profiling provides some
additional interesting data such as a correlation between the
expression of oprD and meropenem resistance [134]. However,
the correlation between the oprD mRNA level and protein
production was only partial, and it was putatively linked to
post-transcriptional regulation. This domain falls within the
research realm and is it not relevant to clinical settings at
present.
5.3. Other possible technologies
In the near future, some emerging technologies could provide
new solutions for detecting β-lactam-resistant bacteria [135].
For example, regarding the phenotypic approach, flow cyto-
metry or microfluidic assays are promising new technologies
that are benefiting from advances in the detection of antimi-
crobial activity at the individual bacterial level [136,137]. Other
technical progress could improve the performance of current
methods; for instance, the BYG Carba Test® is a new electro-
chemical assay that reacts to the pH modifications associated
with imipenem hydrolysis by carbapenemases, and it might fit
with the Carba NP test principle that is based on a pH indi-
cator color change [138]. Numerous other molecular and non-
molecular tests have arisen; thorough and multiple
comparative studies against reference strains and methods
must confirm their putative interest and clinical relevance.
6. Expert commentary
The detection of β-lactam resistance from a clinical speci-
men or a bacterial colony is a top priority for clinical micro-
biologists, since ß-lactam antibiotics remain the most
prescribed antibiotics for humans. A large panel of technical
solutions is increasingly available. Depending on the con-
text, the objective may be the detection of an emerging and
transmissible resistance trait or the evaluation of the clinical
success probability of an antimicrobial therapy. This dual
objective represents the individual and collective
approaches to the problem. This individual purpose primar-
ily relies on the evaluation of the intrinsic susceptibility of
the bacteria for the agent, which is reflected through the
MIC value. To date, there has been no other parameter that
could compete with the MIC determination. Due to the
unavoidable amount of time required to obtain the MIC
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values of classical antibiotic susceptibility testing, the detec-
tion of surrogate targets as other phenotypic traits (bio-
chemical activity or protein detection) or genetic
characteristics constitute an acceptable alternative, and
thus they join the collective objective.
The choice of a given test should be based on the perfor-
mance, reliability, and cost of the given detection assay
(Table 4). Considering the screening approach from an iso-
lated colony, no molecular-based methods could be consid-
ered as a blind first-line test. The future development of the
NGS solution could modify this statement, although the delay,
cost, and interpretation criteria need to be significantly
improved. This position is closely related to the never-ending
diversity of β-lactamases. Therefore, the choice of biochemical
test should rely on its intrinsic performance, which could be
challenged in numerous comparative studies from high-level
publications. To date, the Rapidec Carba NP test® and the
ESBL NP Test® that were challenged in more than 60 publica-
tions constitute an undisputed reference in terms of their
performance/cost ratio. Due to its wide implementation in
clinical laboratories, the MALDI-TOF MS approach is also an
interesting alternative strategy, even though the reference in
terms of a protocol is not established at the moment. As a
second line of investigation, when the β-lactamase type must
be identified or when putative contact carriers have to be
screened after the identification and characterization of an
index case, the narrow-targeted molecular or immunologic
assays constitute acceptable (however imperfect) solutions.
Regarding the performance of these different strategies
when clinical specimens are considered, the molecular
approach could significantly improve the turnaround time of
multidrug-resistant organism detection from stools; nonethe-
less, these results must be controlled using a culture-based
strategy. For the clinical specimens that exhibit a high burden
for a unique pathogen (e.g. a positive blood culture or urine
sample), the performance of rapid phenotypic testing should
be confirmed by additional studies, but they could challenge
molecular assays.
This hierarchy could be debatable and questioned accord-
ing to the availability of new approaches, allowing a faster
determination of the MIC values or an exhaustive molecular
screening.
Considering the costs of some of these assays, which may
be substantial, economic studies focusing on the clinical
relevance of these supplementary expenses must be imple-
mented. Clearly, it will be difficult to demonstrate any clear
and significant impact from these assays, as in cases for
undisputed and new relevant technologies such as MALDI-
TOF. Beyond the technical consideration and performance of
the test, the previously published works have supported the
paramount importance of their incorporation into a virtuous
circle, including the release of local guidelines, and the sub-
stantial counseling availability of infectious disease
specialists.
7. Five-year view
The future of antibiotic efficacy is threatened by the global
spread of MDROs. Taken together, antimicrobial misuse, cross
transmission, and environmental contamination will lead to an
uncontrollable and irreversible situation, particularly in devel-
oping countries. The continuous increase in international
exchange promotes the spread of MDRO. From the pharma-
ceutical industry perspective, the pipeline of new antimicro-
bial products is unlikely to compensate for the increasing
need for effective antibiotics. There is only one option that
actually remains and that is saving antibiotics for triggering
and adapting them as soon as possible for antimicrobial ther-
apy, in combination with a strict infection control policy. For
these purposes, all the field stakeholders, i.e. infectious dis-
eases specialists, infection control practitioners, pharmacists,
and clinical microbiologists, shall rapidly establish decision
algorithms for mixing individual patient risk-factor analysis
and different technologies as culture-based, biochemical, and
molecular methods. These algorithms would be adapted to
the local epidemiology, patient recruitment, and technical and
financial local capacities. Moreover, the development of anti-
microbial stewardship and infection control teams will con-
tinue through the implementation of transversal units of
specialists. Pharmacists will pursue a policy of restrictive access
to last-resort compounds. The cornerstone position of the
clinical laboratory will be strengthened if it has adapted its
technical display and daily operation to local needs. Due to
the decreasing number of laboratories in favor of large con-
centrated platforms, we believe in the development of point-
of-care technologies that will be available at the bedside. In
parallel, the contribution of the cheap and easy-to-use bio-
chemical tests for the characterization of isolated colonies or
pure clinical specimens will be strengthened in practical algo-
rithms of antibiotic initial prescription/de-escalation and infec-
tion control decisions around the world. The culture-based
strategy, which is and will likely continue to be the gold
standard reference method for the next 5 years, is going to
be increasingly challenged by molecular methods, especially
NGS. As exemplified by the latest developments in virology
(HIV, HCV, etc.), we believe that the use of companion diag-
nostics will help to guide clinicians to faster and more ade-
quate antibiotic therapies. To conclude, we believe in a near
future of complimentary approaches to bacteriological diag-
nostics, including culture, biochemistry, biophysical, and mole-
cular techniques, depending on the type of bacteria and
resistance traits to be identified.
Key issues
● The rapid detection of β-lactam resistance is a key element
of antimicrobial stewardship and infection control
strategies
● The extreme variability in the genes and variants responsi-
ble for β-lactam resistance makes it impossible to limit
diagnostics to PCR-based approaches alone
● The biochemical approach is the reference method for first-
line screening purposes
● Efficiency and reliability from cultures to clinical specimens
are essential
● Upon being integrated into an evidence-based algorithm,
their cost is more than acceptable
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● Immunological and molecular assays are of interest for
identifying the primary resistance genes in case of positive
biochemical tests
● During outbreaks, immunological and molecular methods
are of special interest to screen patients when the respon-
sible gene (or the corresponding bacteria) is already
identified
● In the future, the whole genome sequencing approach will
take an increasingly greater place in the detection of resis-
tance genes from strains, clinical specimens or the
microbiome
● All bench-based strategies must be included in a bed-based
antimicrobial stewardship program
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